Search

Search Constraints

You searched for: Author/Creator Boada, Mercè

Search Results

11. A cost‐consequence analysis of early detection of AD in the MOPEAD project — A project within the EU research agenda IMI‐2: Other innovative programs and practices. (7th December 2020)

12. A polygenic risk score for mosaic loss of chromosome Y susceptibility is associated with higher risk of MCI to AD conversion. (1st February 2022)

13. A polygenic risk score for mosaic loss of chromosome Y susceptibility is associated with higher risk of MCI to AD conversion. (December 2021)

14. A Pragmatic, Data-Driven Method to Determine Cutoffs for CSF Biomarkers of Alzheimer Disease Based on Validation Against PET Imaging. (16th August 2022)

15. A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study. Issue 10 (27th July 2020)

16. AB1601 topline results – Phase 2 study of ABvac40 in patients with amnestic mild cognitive impairment (a‐MCI) or very mild Alzheimer's Disease (Vm‐AD). (20th December 2022)

17. Albumin glycation in Alzheimer's disease patients: Results from the AMBAR trial: Molecular and cell biology/protein‐protein interactions. (7th December 2020)

18. Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia. Issue 8 (14th June 2016)

19. Alzheimer's disease risk variants modulate endophenotypes in mild cognitive impairment. Issue 8 (24th February 2016)

20. Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials. Issue 1 (December 2016)